ReviewInternational journal of molecular medicine2025
Emerging role of small RNAs in inflammatory bowel disease and associated colorectal cancer (Review).
Review in International journal of molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The influence of blood levels of circRNAs and microRNAs on the development of ulcerative colitis.Molecular biology reports · 2025Article
- Identification of Salivary Exosome-Derived miRNAs as Potential Biomarkers for Non-Invasive Diagnosis and Proactive Monitoring of Inflammatory Bowel Disease.International journal of molecular sciences · 2025Article
- MicroRNA Gets a Mighty Award.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Diagnostic and Prognostic Significance of a Four-miRNA Signature in Colorectal Cancer.International journal of molecular sciences · 2025Article
- miR-223 alleviates DSS-induced colitis by prompting macrophage M2 polarization through PPAR-γ/FOXO1 signaling.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBDs), which encompasses Crohn's disease and ulcerative colitis, is a chronic inflammatory condition associated with an increased risk of colorectal cancer (CRC). Small RNAs have been linked to various illnesses, including IBD and CRC. These small RNAs also serve as potential biomarkers for these diseases, offering a cutting‑edge approach to investigating possible treatments. To date, treatments involving oral nucleic acid usage are still unachievable due to the instability of medications in the gastrointestinal tract (GIT), their lack of ability to effectively target disease tissues and their notable adverse effects. However, nanoparticle or exosome delivery systems of nucleic acid medications effectively target disease tissues by overcoming the instability of the GIT, resulting in an effective outcome. In the present review, the biogenesis of small RNAs (tRNA‑derived small RNA, microRNA, small nucleolar RNA and p‑element‑induced wimpy testis‑interacting RNA), their roles in the pathogenesis of IBD and CRC as well as their application as possible diagnostic and prognostic biomarkers in IBD and CRC are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.